Pneumococcal conjugate second or third-dose vaccines (PCVc) in Madagascar
Madagascar: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 56.0% in 2025. ◆ Volatile
Latest (2025)
56.0%
Change on year
down 12.5%
World rank
151st
of 194 countries
All-time high
76.0%
in 2013
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Madagascar, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Madagascar recorded 56.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025.
The figure is down 12.5% on the previous year and down 9.7% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Madagascar peaked at 76.0% in 2013 and was at its lowest, 0.0%, in 2008.
Madagascar ranks 151st of 194 countries on this measure, in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Madagascar, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 76.0% | — |
| 2014 | 68.0% | -10.5% |
| 2015 | 62.0% | -8.8% |
| 2016 | 65.0% | +4.8% |
| 2017 | 63.0% | -3.1% |
| 2018 | 73.0% | +15.9% |
| 2019 | 69.0% | -5.5% |
| 2020 | 67.0% | -2.9% |
| 2021 | 56.0% | -16.4% |
| 2022 | 57.0% | +1.8% |
| 2023 | 64.0% | +12.3% |
| 2024 | 64.0% | +0.0% |
| 2025 | 56.0% | -12.5% |
Madagascar compared with similar countries
- Madagascar's 56.0% is below the median for low income countries, which is 80.0%, 70% of the median. (25 countries reporting)
- Madagascar's 56.0% is below the median for Sub-Saharan Africa, which is 82.5%, 68% of the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 47.6% | 0.0% | 76.0% | 10 |
| 2020s | 60.7% | 56.0% | 67.0% | 6 |
Countries ranked near Madagascar
More health data for Madagascar
- Un projection of annual infant deaths, annual growth rate -1.87 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4912 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 920.6 deaths per 1,000 people (2090)
- Number of infants who die before age 1 14,569 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 63 (2025)
- Population ages 00-04, female, annual growth rate 1.32 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.071 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.3 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Madagascar?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Madagascar was 56.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Madagascar?
- The highest recorded value was 76.0% in 2013.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Madagascar?
- The lowest recorded value was 0.0% in 2008.
- How does Madagascar rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Madagascar ranks 151st out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Madagascar?
- Over the last ten years it is down 9.7%. The long-run trend across the full record is volatile.
- Where does this Madagascar data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).